October 2018 - CanadianCannabisWire

WednesdayOct 31, 2018 11:18 am

Phivida Holdings Inc. (CSE: VIDA) (OTCQX: PHVAF) Comments on DEA’s Removal of Cannabidiol from Schedule 1

Phivida’s vision is to help lessen the world’s dependence on pharmaceuticals The company comprises two main brands Phivida recently talked about the removal of CBD from Schedule 1 of the Controlled Substances Act Phivida Holdings Inc. (CSE: VIDA) (OTCQX: PHVAF) is a premium functional food and beverage company. Its focus is whole plant nutrition and natural ingredients. As a result, it infuses organic active hemp extract into an array of premium foods, beverages and clinical products. Phivida’s corporate mission is to help reduce the world’s dependence on pharmaceuticals and provide healthy food and beverage choices. Phivida is headquartered in Vancouver,…

MondayOct 29, 2018 1:17 pm

The Green Organic Dutchman Holdings Ltd. (TSX: TGOD) (OTCQX: TGODF) Advances Expansion Plans through HemPoland Acquisition

The acquisition of HemPoland accelerates opportunities for growth in the European market as part of TGOD’s international strategy The company has received medical sales licensing for its Ancaster, Ontario, facilities – one of many sites where TGOD aims to cultivate cannabis products The company recently closed a $75 million bought deal financing to further its expansion plans in Latin America and Europe Cannabis company The Green Organic Dutchman Holdings Ltd. (TSX: TGOD) (OTCQX: TGODF) has announced the acquisition of HemPoland and the closing of a new bought deal financing, part of several recent developments demonstrating the company’s strong commitment to…

WednesdayOct 24, 2018 10:37 am

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Receives Two US Patents, Bringing Total to 10 in First Patent Family across US and Australia

The two new patents are related to certain cannabinoid-infused beverage compositions using LXRP’s DehydraTECH technology Globally, LXRP has filed some 50 patent applications as the company expands its IP portfolio; LXRP hopes to receive two more granted patents from Australia by year end, giving it 12 in total LXRP out-licenses its technology, which promotes healthier and faster ingestion; the company seeks accelerated patent application examinations in Australia based on the U.S. patents Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) has been granted two new U.S. patents based on cannabinoid-infused beverage compositions using its DehydraTECH ingestion technology platform. The company is…

MondayOct 22, 2018 9:00 am

Canada Leads International Cannabis Boom — and It’s Not About Smoking

CanadianCannabisWire Editorial Coverage: Legal changes in Canada are creating an ideal base for cannabis companies, which are shifting their focus away from smoking. As the first G20 nation to make recreational cannabis legal, Canada is creating an opportunity for its cannabis companies to become global leaders. Analysis shows that the global cannabis market is larger than expected — and set to keep growing. Many new consumers prefer not to smoke their cannabis, leading to a shift towards cannabis-derived food and drinks. Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) (LXRP Profile) has developed patented technology that helps make cannabis available to…

TuesdayOct 16, 2018 11:28 am

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Completes Establishment of Four Wholly Owned Subsidiaries

Lexaria’s technology changes the manner in which edible cannabinoids enter the body The company out-licenses its DehydraTECH drug delivery platform Lexaria recently announced the creation of four wholly owned subsidiaries A research-driven company, Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) is the only company globally that has been awarded a patent for the improved delivery of all cannabinoids. It has developed and out-licenses its DehydraTECH technology – a drug delivery platform. This technology is a complementary layer that works with other research and development being conducted on cannabinoids and, as such, is an enabling technology, not a competing one. Lexaria…

WednesdayOct 10, 2018 12:48 pm

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Infuses Cannabis Industry, Delivers Results with Innovative Drug Delivery Platform

Global legal cannabis market projected to surpass $146 billion by end of 2025 Cannabinoid-infused edibles, concentrates represent fastest-growing segment of industry Lexaria’s patented technology improves bio-absorption and bioavailability of active ingredients while masking unpleasant taste Lucrative licensing business model includes agreements to enhance cannabinoid (CBD) delivery before year-end 2018 Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) and its proprietary technology found in the company’s drug delivery platform DehydraTECH has application for several subsets of the cannabis industry and other pharmacological verticals. As a technology proven to deliver increased intestinal absorption rates and higher bioavailability for a number of bioactive compounds,…

TuesdayOct 09, 2018 12:19 pm

BLOCKStrain Technology Corp. (TSX.V: DNAX) (OTC: BKKSF) Signs Partnership with Lighthouse Genomics, Inc.

Technology partnership signed with Integral Genomics Inc. (dba Lighthouse Genomics Inc.) to support BLOCKStrain’s registry of genetic profiles of cannabis strains Valuable intellectual property rights of cannabis cultivators under attack from unscrupulous illegal growers, gray market Recent reschedule of first FDA-approved drug derived from cannabis paves the way for sales, underscores necessity of BLOCKStrain’s “Single Source of Trust” registry Legislation efforts growing in U.S. as Canada readies recreational cannabis sales throughout nation Global legal cannabis market projected to reach $146.4 billion by end of 2025 In a move crafted to support advancements in science and technology within the legal cannabis…

ThursdayOct 04, 2018 10:08 am

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Plans to Grow its Global Patent Application Portfolio to 150-200 within Two Years

LXRP files for tenth patent family, expanding the applicability of its DehydraTECH platform relating to tobacco leaves delivering compounds that may or may not include nicotine LXRP receives three new Australian patents and two new notices of allowance from the U.S.; if all are issued, LXRP would then hold 12 issued patents within its first patent family The company out-licenses its technology that promotes healthier and faster ingestion methods in any country where it already has a patent or is patent-pending Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP), which owns the patented DehydraTECH ingestion technology platform, is building its strategic…

ThursdayOct 04, 2018 9:00 am

Intangible Assets Power Growth, Acquisitions in the Pharmaceuticals Sector

CanadianCannabisWire Editorial Coverage: Intangible assets such as patents increasingly dominate the global business landscape, especially in the pharmaceutical sector. Intangible assets are estimated to be worth trillions of dollars in the United States alone. These assets drive deals as companies acquire smaller patent holders. In growing sectors such as cannabis, smaller companies are rushing to establish intangible assets ready for expected market growth. Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) (LXRP Profile) is one of the leaders in the world of cannabis, with applications made for more than 50 different patents and more to come. Tilray Inc. (NASDAQ: TLRY) is also…

WednesdayOct 03, 2018 12:36 pm

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) Partners with Asterion Cannabis to Develop Organic Cannabinoid Products

PreveCeutical Medical Inc. enters into a joint venture agreement with Asterion Cannabis Inc. to develop several nature-based cannabinoid products; the products will help the company respond to the demands for personalized and effective cannabis therapies The development agreement will see Asterion inject funds at cost, while PreveCeutical will contribute by way of opening its research resources, including personnel for use in the project The percentage ownership of intellectual and product rights from the agreement will be shared between Asterion and PreveCeutical in the ratio of 80 percent to 20 percent Since the agreement involves related parties including current and former…

News and Publishing Service for Cannabis Related, Canadian Companies

Contact us: 905.674.5977

Month: October 2018